BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash

A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino ("HSR") Antitrust Improvements Act.